Physician profile
Natasha Ferguson
NPI 1235443276
$7,407.45
in general payments reported to CMS, 2019-2025
41 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $692 · 2021: $1,129 · 2022: $1,452 · 2023: $1,175 · 2024: $1,278 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,505.91 |
| Education | $208.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,230.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $946.10 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $925.01 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $603.71 | 2019-2025 | Breztri, Fasenra, Farxiga |
| Pfizer INC. | $544.94 | 2019-2025 | |
| Astellas Pharma US INC | $312.68 | 2019-2025 | Veozah |
| Abbvie INC. | $274.71 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $237.17 | 2019-2022 | |
| Exact Sciences Corporation | $229.28 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.41 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.12 | 2020-2025 | Xifaxan, Trulance |
| Shield Therapeutics INC | $156.68 | 2025 | |
| Currax Pharmaceuticals LLC | $150.72 | 2021-2023 | Nexletol, Contrave, Onzetra Xsail |
| Janssen Pharmaceuticals, INC | $139.85 | 2021-2023 | Xarelto |
| Genzyme Corporation | $116.50 | 2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.